SAN FRANCISCO, CA--(Marketwire - September 08, 2011) -
Linkage Biosciences, Inc., a molecular diagnostics company and leader in molecular HLA typing products, announced that it raised over $2 million in Series B financing. Linkage Biosciences' LinkSēq™ HLA product line uses a proprietary software and chemistry platform in conjunction with real-time PCR instrumentation. This combination of technologies provides significant improvements in the analysis of complex genetic regions including reducing labor requirements by up to 85% compared to current methods.
Fisher Capital Corp LLC and Greenhouse Capital Partners led the round with all major existing investors from previous rounds participating including Big Sky Partners. "This is an exciting time in the maturation of Linkage Biosciences," said James R. Fisher Sr., Managing Member of Fisher Capital Corp LLC. "With this financing, the company is now positioned to scale up operations to capitalize upon its revolutionary LinkSēq technology."
Zachary Antovich, Linkage's CEO, said the funds will be used to expand manufacturing capabilities, complete regulatory requirements in the US and Europe, and increase the speed to market of additional molecular tests. "Our commercialization plans and technology are progressing rapidly," said Mr. Antovich. "The strong support from our current investors is the result of our continued success in achieving milestones and delivering products that meet or exceed the expectations of our customers."
About Linkages Biosciences
Linkage Biosciences, Inc. is a privately held molecular diagnostics company developing and marketing products that dramatically improve and expedite complex genetic testing. LinkSēq, the company's HLA testing product line, is used in immunogenetics research. The company is headquartered in San Francisco, California. To learn more please visit www.linkagebio.com.
Copyright 2011. Linkage Biosciences, Inc. All rights reserved.
Linkage Biosciences and LinkSēq are trademarks of Linkage Biosciences, Inc.